^
Association details:
| Biomarker: | PD-L1 overexpression + RET-CCDC6 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
Published date:
03/15/2022
Excerpt:
...we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice....A 65-year-old woman...diagnosis of adenocarcinoma with 70% of PD-L1 TPS...Molecular testing confirmed CCDC6-RET fusion...pembrolizumab treatment was initiated in February 2020. Progressive disease (mediastinal lymph nodes progression, new lung nodules, bone lesions, and liver metastases) was found on CT which was performed three months later in May 2020...
DOI:
https://doi.org/10.3390/jcm11061630
Source:
Title:
P78.10 Immunotherapy in Non-Small Cell Lung Cancer with High PD-L1 Expression and Coexistent RET- Fusion: The Description of Two Cases.
Published date:
01/12/2021
Excerpt:
...stage IV NSCLC adenocarcinoma - PD-L1 70%, RET-fusion CCDC6 [1]-RET[12] was found. Pembrolizumab was administered, but 3 months later PD was found...Despite the high PD-L expression (observed seldom in patients with RET abnormalities) no benefit of immunotherapy was observed in our patients.
